US20020015944A1 - Herpes simplex virus 1 UL 13 gene product: methods and compositions - Google Patents
Herpes simplex virus 1 UL 13 gene product: methods and compositions Download PDFInfo
- Publication number
- US20020015944A1 US20020015944A1 US09/870,931 US87093101A US2002015944A1 US 20020015944 A1 US20020015944 A1 US 20020015944A1 US 87093101 A US87093101 A US 87093101A US 2002015944 A1 US2002015944 A1 US 2002015944A1
- Authority
- US
- United States
- Prior art keywords
- herpes simplex
- gene product
- gene
- simplex virus
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 14
- 241000700588 Human alphaherpesvirus 1 Species 0.000 title description 18
- 101150025032 13 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 130
- 241000700584 Simplexvirus Species 0.000 claims abstract description 37
- 230000003612 virological effect Effects 0.000 claims abstract description 16
- 208000009889 Herpes Simplex Diseases 0.000 claims abstract description 12
- 230000003602 anti-herpes Effects 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 230000000865 phosphorylative effect Effects 0.000 claims abstract description 5
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims description 32
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims description 32
- 239000000758 substrate Substances 0.000 claims description 25
- 230000026731 phosphorylation Effects 0.000 claims description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 10
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 101150096316 5 gene Proteins 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 101150053996 UL47 gene Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 101001042070 Equine herpesvirus 1 (strain V592) E3 ubiquitin-protein ligase ICP0 Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 60
- 241000700605 Viruses Species 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 49
- 239000000047 product Substances 0.000 description 40
- 102000001253 Protein Kinase Human genes 0.000 description 23
- 108060006633 protein kinase Proteins 0.000 description 23
- 108010089430 Phosphoproteins Proteins 0.000 description 21
- 102000007982 Phosphoproteins Human genes 0.000 description 21
- 239000000284 extract Substances 0.000 description 16
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 108060002716 Exonuclease Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000013165 exonuclease Human genes 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 101710130522 mRNA export factor Proteins 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 101150090364 ICP0 gene Proteins 0.000 description 5
- 101150085955 US11 gene Proteins 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 241000894007 species Species 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 238000000211 autoradiogram Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101150003725 TK gene Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 101150060044 UL26 gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 101150087698 alpha gene Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229920001940 conductive polymer Polymers 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000006648 viral gene expression Effects 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800000342 Glycoprotein C Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 1
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710178472 Tegument protein Proteins 0.000 description 1
- 101710192321 Tegument protein VP16 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101150095805 UL7 gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- -1 threonine amino acids Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/035—Herpes simplex virus I or II
Definitions
- the present invention relates to the gene product of a herpes simplex virus U L 13 gene and the use of that gene product in an assay for screening substances for their anti-herpes simplex viral activity.
- the herpes simplex virus 1 (HSV-1) genome encodes at least 76 genes (McGeoch, et al., 1985; Chou, et al., 1986; McGeoch, et al., 1988; Liu, et al, 1991; Barker, et al., 1992). Inasmuch as three of the genes are contained within repeated sequences, the genome encodes at least 73 polypeptides.
- the 76 genes comprise several groups designated as ⁇ , ⁇ , and ⁇ , whose expression is coordinately regulated and sequentially ordered in a cascade fashion (Honess, et al., 1974). For the past two decades, this laboratory has investigated the mechanisms by which HSV-1 regulates the expression and function of its genes.
- HSV-1 U S 3 and U L 13 gene products contain motifs common to known protein kinases (McGeoch, et al., 1985; McGeoch, et al., 1988; McGeoch, et al., 1986; Smith, et al., 1989).
- U S 3 PK the most prominent target of the U S 3 PK is an essential, non glycosylated membrane protein encoded by a highly conserved herpesvirus gene, U L 34 (Purves, et al., 1991; Purves, et al., 1992).
- U S 3 the nonphosphorylated U L 34 protein associates with several phosphorylated proteins not demonstrable in cells infected with wild type virus.
- the U S 11 protein may act as an antiterminator of transcription of U L 34 inasmuch as (i) significant amounts of a truncated U L 34 mRNA accumulate in cells infected with a U S 11 ⁇ virus and (ii) the U S 11 protein binds to U L 34 mRNA immediately 5′ to the truncation (Roller, et al., 1991).
- the functions of the U L 34 protein remain unknown, the regulation of its synthesis and expression deduced from the activities of U S 11 and U S 3 protein attest to its role in the reproductive cycle of the virus. Very little is known about the targets of the U L 13 PK.
- U L 13 In the processing of the U L 34 protein, we constructed viral mutants lacking either the U L 13 gene or both the U L 13 and U S 3 genes. We report that a substrate of U L 13 PK is the product of the regulatory gene, ⁇ 22.
- the present invention relates to a process of identifying a substance for its anti-herpes simplex viral ability comprising the steps of:
- a substrate used in a process of the present invention is herpes simplex virus infected cell protein 0, herpes simplex virus infected cell protein 22, herpes simplex virus US11 gene product, herpes simplex virus UL26 gene product, herpes simplex virus UL26.5 gene product or herpes simplex virus UL7 gene product.
- a model system of phosphorylating such a substrate preferably contains an effective catalytic amount of a herpes simplex virus U L 13 gene product.
- such a model system is prepared by forming an admixture by reacting an effective catalytic amount of herpes simplex virus U L 13 gene product with an effective amount of a substrate whose phosphorylation is catalysed by said herpes simplex virus U L 13 gene product in a liquid medium containing a phosphate donor.
- FIG. 1 shows schematic representations of the DNA sequence arrangements of the HSV-1 genome of deletion mutants.
- the top line the genome of HSV-1(F) ⁇ 305 from which approximately 500 bp of the thymidine kinase (tk gene had been deleted (Post, et al., 1981).
- the rectangles represent the inverted repeats flanking the unique sequences (thin lines) of the long and short components.
- the location of the tk gene is marked (TK) Line 1, relevant restriction enzyme sites present in the U L 12- 14 genes shown on line 4.
- Lines 2 and 3 the EcoRV P and Bg1II O fragments, respectively.
- Line 5 the 581 amino acid U L 13 gene with protein kinase motifs located between the BstEII and HindIII cleavage sites their position is represented by the shaded rectangle.
- Line 6 the U L 13 gene of R7350 and R7354 viruses. In these recombinants an ⁇ 27-l chimeric gene from pRB3968 was inserted into the BstEII site of the 2691 bp EcoRV P fragment cloned in the SmaI site of pGEM3z in pRB256.
- the resulting plasmid pRB4435 was cotransfected with intact R7040 or HSV-1(F) ⁇ 305 DNAs into rabbit skin cells and tk+ progeny viruses were selected in 143TK ⁇ cells as described (Post, et al., 1981) and designated as R7350 and R7354, respectively C(able 1).
- Recombinant virus R7350 also harbors the deletion in the U S 3 gene described previously (Longnecker, et al., 1987) and shown in line 12.
- Recombinant R7351 and R7355 were constructed by co-transfection of R7350 or of R7054 viral DNA with plasmid pRB4439 followed by selection of tk progeny as described (Post, et al., 1981). Removal of the HindIII-BstEII fragment deleted 45% of the U L 13 codons (amino acid 155 to 412 including the predicted conserved PK motifs). Recombinants R7352, R7357, and R7358 were constructed by marker rescue of recombinant viruses R7351, R7350 and R7354, respectively. Plasmid pRB4437 was co-transfected with intact viral DNAs and the progeny were selected for tk ⁇ (R7357 and R7358).
- FIG. 2 shows autoradiographic images of Bg1II digests of recombinant viral DNAs.
- Viral DNAs were prepared from NaI gradients as previously described (Walboomers, et al., 1976), digested with Bg1II, electrophoretically separated on 0.8% agarose gels, transferred to nitocellulose membranes, and hybridized with radiolabeled pRB4004, which contains the HSV-l(F) Bg1II O fragment.
- the band designated 5.2 Kbp represents the wild-type Bg1II O fragment present in recombinant viruses HSV-1(F) ⁇ 305 and R7040 ( ⁇ U S 3).
- the 6.7kb band represents the Bg1II O fragment containing the ⁇ 27-tk gene in the U L 13 gene in recombinant viruses R7350 ( ⁇ U S 3, U L 13i) and R7354 (U L 13i).
- the 4.4kb bands detected in recombinant viruses R7351 ( ⁇ U S 3, ⁇ U L 13) and R7355 ( ⁇ U L 13) represent the Bg1II O fragment of these viruses harboring a 773 bp deletion in the ⁇ U L 13 gene.
- FIG. 3 shows autoradiographic and photographic images of electrophoretically separated phosphoproteins from infected HEp2 cell nuclei:
- Panel A represents 32 P-labled phosphoprotein profile of nuclear extracts of infected Hep2 cells electrophoretically separated in denaturing 8.5% acrylamide gels, transferred to nitrocellulose and reacted with monoclonal antibody (Q1) to alkaline exonuclease as shown in panel B.
- Q1 monoclonal antibody
- the arrow indicates the 85,000 Mr alkaine exonuclease designated as ICP18.
- the faint, faster migrating species reacting with the antibody has been identified previously as a degradation product of alkaline exonuclease.
- infected labeled HEp2 cell monolayers were washed with PBS-A and scraped into PBS-A and pelleted by centrifugation.
- the cells were disrupted with PBS-A containing 0.5% NP40 and the nuclei were pelleted by centrifugation, washed with PBS-A containing 0.1% NP40, extracted for 30 min at 4° C.
- FIG. 4 shows autoradiographic images of electrophoretically 32 p and 35 S-labeled lysates of infected BHK cells. The procedures for infection, radiolabeling and preparation of cell lysates were described elsewhere (Purves, et al., 1991; Purves, et al., 1992).
- Panel A autoradiogram of 32 P-labeled proteins separated in denaturing gels containing 10% acrylamide. The closed circle indicate the increased amounts of the 70kd phosphoprotein observed in lysates of BHK cells infected with the U L 13i or ⁇ U L 13 viruses. The letters a-d indicate the four new phosphoproteins which are present in cells infected with ⁇ U S 3 viruses. The solid square indicates the position of the U L 34 protein. The molecular weight standards are indicated.
- Panel B autoradiogram of 35 S-methionine labeled proteins separated as described above. The positions of known ICPs are indicated.
- FIG. 5 shows photographic and autoradiographic images of electrophoretically separated 32 P-labeled and 35 S-methionine labeled lysates of infected cells.
- Panel A photograph of proteins electrophoretically separated in 8.5% acrylamide denaturing gels, transferred to nitrocellulose and reacted first with a polyclonal R77 antiserum specific for ICP22, and then with monoclonal antibody H1117 to ICP27 as a control for equal infectivity.
- the five forms of ICP22 protein are indicated in lanes 2 and 20, and the position of ICP27 is indicated by the single arrow in panel A.
- Panel B represents the corresponding autoradiogram
- lanes 1-12 are separated infected cell proteins labeled with 32P
- lanes 13-20 are separated infected cell proteins labeled with 35S-methionine.
- Known ICPs are indicated by arrows, and a M r 67,000 marker is included.
- FIG. 6 shwos autoradiographic and photographic images of 32P-labeled nuclear extracts from infected HE2 cells.
- Panel A autoradiogram of 32 P-labled nuclear extract proteins sated in denaturing gels containing 8.5% acrylamide.
- Panel B photograph of the corresponding gel shown in panel A transferred to nitroceflulose and reacted with polyclonal antiserum R77 to ICP22.
- Panel C lanes 16-22 represent a lower exposure of the same HEp2 nuclear extracts of 32 P-labeled proteins infected with the indicated viruses as shown in panel A. The preparation of labeled nuclear extract is described in the legend to FIG. 3. Nuclear extract proteins were separated in an 8.5% polyacrylamide gel.
- Lanes 23-27 show HEp2 nuclear extracts which have been labeled with ⁇ 32 P-ATP in the presence of 1M NaCl in vitro.
- the five forms of ICP22 are indicated by the numbers 1-5.
- the positions of ICP18 (alkaine exonuclease; M r 85,000), ICP25 ( ⁇ TIF, M r 65,000), ICP27 (M r 63,000), and of U L 34 (M r 30,000) protein represented by the square are indicated.
- the letters U, T, S, R, and Q in panel C identify the phosphoprotein of nuclear extracts of infected HEp2 cells labeled with ⁇ 32 p ⁇ ATP in vitro.
- Approximately 2 ⁇ g of nuclear extract was suspended in 50 ⁇ l of kinase buffer containing 50 mM Tris HCl, 1M NaCl, 0.1% NP40, 50mM KCl, 20mM MgCl 2 , 3 mM MgAc, 1 mM dithiothreitol, and 5 ⁇ Ci of ⁇ 32 p-ATP and incubated at 37° C. for 20 mins. The reactions were terminated by denaturation with sodium dodecyl sulfate.
- the present invention provides a process of identifying a substance for its anti-herpes simplex viral ability. Such a process comprises the steps of:
- the expression product of herpes simplex virus gene U L 13 catalyses the transfer of a phosphate moiety from a phosphate donor to a substrate. That is, the U L 13 gene product functions as a protein kinase.
- Substrates for the U L 13 gene product protein kinase include a number of proteins found in herpes simplex virus infected cells and proein products of particular herpes simplex gene expression.
- Exemplary and preferred infected cell protein (ICP) substrates are designated ICP0 and ICP22.
- ICP22 is a gene product of herpes simplex virus regulatory gene ⁇ 22. ICP22 is also referred to herein as ⁇ 22 protein.
- Exemplary and preferred gene product substrates are the gene products of herpes simplex virus US11 gene, herpes simplex virus U L 26 gene, herpes simplex virus UL26.5 gene or herpes simplex virus UL47 gene.
- the herpes simplex virus UL26 gene product functions as a protease enzyme.
- Herpes simplex virus UL26.5 gene product is thought to be a substrate for that protease.
- the herpes simplex virus US11 gene product acts as an anti-terminating agent for transcription of the U L 34 gene.
- At least some of the substrates of U L 13 gene product kinase activity play a role in viral replication and appear late in viral infection. Where infection occurs with a virus deficient in U L 13 gene product expression, viral replication is inhibited and those substrate molecules are altered (ICP22, the UL47 gene product) or substantially decreased in abundance (the US11, U126, UL26.5 gene products).
- a model system for studying phosphorylation of U L 13 gene product substrates preferably comprises an effective catalytic amount of a herpes simplex virus U L 13 gene product.
- such a model system is prepared by forming an admixture by reacting an effective catalytic amount of herpes simplex virus U L 13 gene product with an effective amount of a substrate whose phosphorylation is catalysed by said herpes simplex virus U L 13 gene product in a liquid medium containing a phosphate donor.
- S Herpes simplex virus U L 13 gene product is preferably obtained from cells or organisims infected with the virus. Means for isolating and purifying products of viral gene expression in infected cells are well known in the art. A suitable substrate for use in a process of the present invention can also be obtained from infected cells.
- the herpes simplex virus 1 U L 13 gene encodes the functions for post-translational processing associated with phosphorylation of the regulatory protein ⁇ 22.
- the U L 13 gene is non-essential in cell culture.
- viruses designated with an (R) in which the deleted sequences were restored by marker rescue with a small fragment. All four recombinant viruses replicated on rabbit skin, 143TK ⁇ , HEp2, Vero, and BHK cells. During construction of the recombinant viruses, however, it was noted that viruses deleted in the U L 13 gene ( ⁇ U L 13) yielded fewer plaques which were also of smaller size than those of the wild type virus, a property shared with mutants in the U L 12 gene encoding the alkaline exonuclease (Weller, et al., 1990).
- novel phosphoproteins present in cells infected with the ⁇ US3 viruses are not dependent upon the U L 13 gene product.
- Phosphoprotein U was identified as the alkaline exonuclease by its reactivity with the Q1 monoclonal antibody. Phosphoprotein T is presently under investigation. Phosphoprotein Q, however, which has an apparent M r of 57,000, is present only in cells infected with viruses encoding an intact U L 13 gene.
- the U L 13 protein like the U S 3 PK, is non-essential for HSV-1 replication in cell culture, although viral yields appear to be diminished.
- the predicted sequence of the U L 13 protein contains amino acid motifs which are characteristic of the catalytic domains of eukaryotic PKs, and possibly bacterial phosphotransferases (Smith, et al., 1989; Chee, et al., 1989).
- U S 3 PK Purves, et al., 1986; Purves, et al., 1987; Purves, et al., Eur. J. Biochem. 1987
- determination of the enzymatic activity will require studies on purified protein.
- the U S 3 PK is mainly a cytoplasmic kinase (Purves, et al., 1986), the U L 13 protein is readily detected in the nucleus (Cunningham, et al., 1992).
- the major substrate of the U S 3 PK is the U L 34 membrane protein (Purves, et al., 1992), the prominent target of U L 13 is ICP22.
- U S 3 is conserved only among the alphaherpesviruses (McGeoch, et al., 1986; Baer, et al., 1984; Davison, et al, 1986)
- the U L 13 gene is conserved among all three herpesvirus subfamilies (varicella zoster, (Davison, et al, 1986), human cytomegalovirus, (Chee, et al., 1989), human herpes virus 6, (Lawrence, et al., 1990) and Epstein Barr Virus, (Baer, et al., 1984).
- the M r 70,000 species (No. 5) of ICP22 and trace amounts of higher mol. weight species (No. 24) predominate in extracts of cells infected with the U L 13 ⁇ viruses.
- the stepwise increases in molecular weight between the five ICP22 subspecies are consistent with, but not indicative of, successive phosphorylations of the protein and appear to be cell type specific.
- the phosphorylation of the Mr. 70,000 species (No. 5) is independent of the U L 13 protein.
- Subsequent phosphorylation of ICP22 may represent direct phosphorylations by the U L 13 protein or by another infected cell PK activated by the U L 13 gene product.
- ICP22 is predicted to have 45 serine and 28 threonine amino acids.
- ICP22 has been implicated in the trans-activation of viral genes and as a protein involved in extending the host range of HSV-1 in cell culture (Sears, et al., 1985). In non permissive cells (e.g. rabbit skin, hamster, and rat cell lines) late protein synthesis was grossly reduced. ICP22 appears to exert a regulatory function which is complemented by cellular proteins in some cell lines. Since ICP22 is among the first. viral proteins made after infection, it is conceivable that the U L 13 protein modifies ICP22 late in infection thereby altering its function. In this respect, the U L 13 gene may serve to regulate late gene expression via ICP22.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides the gene product of the herpes simplex virus UL13 gene as being capable of phosphorylating other gene products of the herpes simplex virus. The herpes simplex virus UL13 gene product is used in an assay to identify substances suspected of having anti-herpes simplex viral activity.
Description
- The present invention relates to the gene product of a herpes
simplex virus U L13 gene and the use of that gene product in an assay for screening substances for their anti-herpes simplex viral activity. - The herpes simplex virus 1 (HSV-1) genome encodes at least 76 genes (McGeoch, et al., 1985; Chou, et al., 1986; McGeoch, et al., 1988; Liu, et al, 1991; Barker, et al., 1992). Inasmuch as three of the genes are contained within repeated sequences, the genome encodes at least 73 polypeptides. The 76 genes comprise several groups designated as α,β, and γ, whose expression is coordinately regulated and sequentially ordered in a cascade fashion (Honess, et al., 1974). For the past two decades, this laboratory has investigated the mechanisms by which HSV-1 regulates the expression and function of its genes. In the course of these studies, we demonstrated that (i) initiation of transcription of viral genes is induced by a structural component of the virion (Post, et al., 1981; Batterson, et al., 1983), (ii) regulatory proteins induced by this process are phosphorylated (Pereira, et al., 1977; Marsden, et al., 1978) and (iii) binding of these proteins to DNA is affected by phosphorylation (Wilcox, et al., 1980). Since protein kinases (PK) are known to affect the function of regulatory proteins, we sought to identify the substrates of viral PKs and clarify their function.
- Both HSV-1
U S3 andU L13 gene products contain motifs common to known protein kinases (McGeoch, et al., 1985; McGeoch, et al., 1988; McGeoch, et al., 1986; Smith, et al., 1989). Definitive evidence ofU S3 PK activity emerged from the observations that (i) the novel enzyme activity detected in cells infected with wild type virus was absent from uninfected cells and cells infected with a mutant from which theU S3 gene had been deleted (Purves, et al., 1986; Frame, et al., 1987), and (ii) antibody raised against a synthetic eight-amino acid C-terminal U S3 oligopeptide reacted with purified preparations of the enzyme (Frame, et al., 1987). Recently, we demonstrated that the most prominent target of theU S3 PK is an essential, non glycosylated membrane protein encoded by a highly conserved herpesvirus gene, UL34 (Purves, et al., 1991; Purves, et al., 1992). In the absence ofU S3, the nonphosphorylated UL34 protein associates with several phosphorylated proteins not demonstrable in cells infected with wild type virus. Concurrently, it was shown that theU S11 protein may act as an antiterminator of transcription of UL 34 inasmuch as (i) significant amounts of a truncated UL34 mRNA accumulate in cells infected with aU S11− virus and (ii) theU S11 protein binds to UL34 mRNA immediately 5′ to the truncation (Roller, et al., 1991). Although the functions of the UL34 protein remain unknown, the regulation of its synthesis and expression deduced from the activities ofU S11 andU S3 protein attest to its role in the reproductive cycle of the virus. Very little is known about the targets of the UL13 PK. To investigate the role ofU L13 in the processing of the UL34 protein, we constructed viral mutants lacking either theU L13 gene or both theU L13 andU S3 genes. We report that a substrate ofU L13 PK is the product of the regulatory gene, α22. - In one aspect the present invention relates to a process of identifying a substance for its anti-herpes simplex viral ability comprising the steps of:
- a) preparing a model system of phosphorylating a substrate of the herpes
simplex virus U L13 gene product; - b) selecting a substance suspected of having anti-herpes simplex viral acivity; and
- c) testing for the ability of said substance to modulate phosphorylation of said substrate and thus anti-herpes simplex viral acivity in said model system.
- In a preferred embodiment, a substrate used in a process of the present invention is herpes simplex virus infected cell protein 0, herpes simplex virus infected
cell protein 22, herpes simplex virus US11 gene product, herpes simplex virus UL26 gene product, herpes simplex virus UL26.5 gene product or herpes simplex virus UL7 gene product. - A model system of phosphorylating such a substrate preferably contains an effective catalytic amount of a herpes
simplex virus U L13 gene product. - In a preferred embodiment, such a model system is prepared by forming an admixture by reacting an effective catalytic amount of herpes
simplex virus U L13 gene product with an effective amount of a substrate whose phosphorylation is catalysed by said herpessimplex virus U L13 gene product in a liquid medium containing a phosphate donor. - In the drawings which form a portion of this specification:
- FIG. 1 shows schematic representations of the DNA sequence arrangements of the HSV-1 genome of deletion mutants. The top line: the genome of HSV-1(F)Δ305 from which approximately 500 bp of the thymidine kinase (tk gene had been deleted (Post, et al., 1981). The rectangles represent the inverted repeats flanking the unique sequences (thin lines) of the long and short components. The location of the tk gene is marked (TK)
Line 1, relevant restriction enzyme sites present in the UL12-14 genes shown online 4. 2 and 3, the EcoRV P and Bg1II O fragments, respectively.Lines Line 5, the 581amino acid U L13 gene with protein kinase motifs located between the BstEII and HindIII cleavage sites their position is represented by the shaded rectangle.Line 6, theU L13 gene of R7350 and R7354 viruses. In these recombinants an α27-l chimeric gene from pRB3968 was inserted into the BstEII site of the 2691 bp EcoRV P fragment cloned in the SmaI site of pGEM3z in pRB256. The resulting plasmid pRB4435 was cotransfected with intact R7040 or HSV-1(F)Δ305 DNAs into rabbit skin cells and tk+ progeny viruses were selected in 143TK− cells as described (Post, et al., 1981) and designated as R7350 and R7354, respectively C(able 1). Recombinant virus R7350 also harbors the deletion in theU S3 gene described previously (Longnecker, et al., 1987) and shown inline 12.Line 7, schematic representation of the sequences extending from the HindIII site (amino acid 155) to the BstEII site (amino acid 412) deleted from theU L13 gene.Line 8, the DNA arrangement of recombinant viruses R7352, R7357 and R7358 in which theU L13 sequences disrupted by the insertion or which had been deleted were restored by marker rescue with the MscI-KpnI fragment. Thus, the 2223 bp KpnI-MscI fragment from pRB4004 containing the HSV-1 Bg1II O was excised and cloned into the EcoRV site of pGEM5z to yield plasmid pRB4437. The pRB4437 DNA was cleaved with HindIII and BstEII, blunt ended with T4 polymerase and religated to yield pRB4439. Recombinant R7351 and R7355 were constructed by co-transfection of R7350 or of R7054 viral DNA with plasmid pRB4439 followed by selection of tk progeny as described (Post, et al., 1981). Removal of the HindIII-BstEII fragment deleted 45% of theU L13 codons (amino acid 155 to 412 including the predicted conserved PK motifs). Recombinants R7352, R7357, and R7358 were constructed by marker rescue of recombinant viruses R7351, R7350 and R7354, respectively. Plasmid pRB4437 was co-transfected with intact viral DNAs and the progeny were selected for tk− (R7357 and R7358). The progeny of individual plaques were examined for the presence of an intact 5.2 Kbp Bg1II O fragment.Line 9, areas of the relevant BamHI fragments which contain the genes US1 (α22),U S2, U3 (PK), US4 (glycoprotein G), andU S5, shown inline 10.Line 11, the 481amino acid U S3 gene with conserved protein kinase motifs represented by the shaded rectangle.Line 12, schematic representation of theU S3 sequences spanning from the PstI site atamino acid 69 to the BamHI site atamino acid 357 deleted from R7040, R7041, R7350 and R7351 viruses.Line 13, representation of the region of R7306 in which the deletedU S3 PK sequences of R7041 have been restored by marker rescue. - FIG. 2 shows autoradiographic images of Bg1II digests of recombinant viral DNAs. Viral DNAs were prepared from NaI gradients as previously described (Walboomers, et al., 1976), digested with Bg1II, electrophoretically separated on 0.8% agarose gels, transferred to nitocellulose membranes, and hybridized with radiolabeled pRB4004, which contains the HSV-l(F) Bg1II O fragment. The band designated 5.2 Kbp represents the wild-type Bg1II O fragment present in recombinant viruses HSV-1(F)Δ305 and R7040 (ΔU S3). The 6.7kb band represents the Bg1II O fragment containing the α27-tk gene in the
U L13 gene in recombinant viruses R7350 (ΔU S3, UL13i) and R7354 (UL13i). The 4.4kb bands detected in recombinant viruses R7351 (ΔUS3, ΔUL13) and R7355 (ΔUL13) represent the Bg1II O fragment of these viruses harboring a 773 bp deletion in theΔU L13 gene. - FIG. 3 shows autoradiographic and photographic images of electrophoretically separated phosphoproteins from infected HEp2 cell nuclei: Panel A represents 32P-labled phosphoprotein profile of nuclear extracts of infected Hep2 cells electrophoretically separated in denaturing 8.5% acrylamide gels, transferred to nitrocellulose and reacted with monoclonal antibody (Q1) to alkaline exonuclease as shown in panel B. The arrow indicates the 85,000 Mr alkaine exonuclease designated as ICP18. The faint, faster migrating species reacting with the antibody has been identified previously as a degradation product of alkaline exonuclease. To prepare nuclear extracts, infected labeled HEp2 cell monolayers were washed with PBS-A and scraped into PBS-A and pelleted by centrifugation. The cells were disrupted with PBS-A containing 0.5% NP40 and the nuclei were pelleted by centrifugation, washed with PBS-A containing 0.1% NP40, extracted for 30 min at 4° C. in a buffer (50 mM Tris-HCl pH 7.5, 0.42M NaCl, 25% glycerol, 10% sucrose, 5mM MgCl2, 0.1 mM EDTA, 0.1% NP40, 0.1M KCl, 1mM DTT, 1mM PMSF), clarified by centrifugation and stored at −70° C. The procedures for electrophoretic separation in denaturing 8.5% or 10% polyacrylamide gels, electric transfer to nitrocellulose and staining with antibodies to specific HSV-1(F) proteins and or autoradiography were as previously described (Purves, et al., 1991; Purves, et al., 1992).
- FIG. 4 shows autoradiographic images of electrophoretically 32p and 35S-labeled lysates of infected BHK cells. The procedures for infection, radiolabeling and preparation of cell lysates were described elsewhere (Purves, et al., 1991; Purves, et al., 1992). Panel A: autoradiogram of 32P-labeled proteins separated in denaturing gels containing 10% acrylamide. The closed circle indicate the increased amounts of the 70kd phosphoprotein observed in lysates of BHK cells infected with the UL13i or
ΔU L13 viruses. The letters a-d indicate the four new phosphoproteins which are present in cells infected withΔU S3 viruses. The solid square indicates the position of the UL34 protein. The molecular weight standards are indicated. Panel B: autoradiogram of 35S-methionine labeled proteins separated as described above. The positions of known ICPs are indicated. - FIG. 5 shows photographic and autoradiographic images of electrophoretically separated 32P-labeled and 35S-methionine labeled lysates of infected cells. Panel A: photograph of proteins electrophoretically separated in 8.5% acrylamide denaturing gels, transferred to nitrocellulose and reacted first with a polyclonal R77 antiserum specific for ICP22, and then with monoclonal antibody H1117 to ICP27 as a control for equal infectivity. The five forms of ICP22 protein are indicated in
2 and 20, and the position of ICP27 is indicated by the single arrow in panel A. Panel B, represents the corresponding autoradiogram, lanes 1-12 are separated infected cell proteins labeled with 32P and lanes 13-20 are separated infected cell proteins labeled with 35S-methionine. Known ICPs are indicated by arrows, and a Mr 67,000 marker is included.lanes - FIG. 6 shwos autoradiographic and photographic images of 32P-labeled nuclear extracts from infected HE2 cells. Panel A: autoradiogram of 32P-labled nuclear extract proteins sated in denaturing gels containing 8.5% acrylamide. Panel B: photograph of the corresponding gel shown in panel A transferred to nitroceflulose and reacted with polyclonal antiserum R77 to ICP22. Panel C: lanes 16-22 represent a lower exposure of the same HEp2 nuclear extracts of 32P-labeled proteins infected with the indicated viruses as shown in panel A. The preparation of labeled nuclear extract is described in the legend to FIG. 3. Nuclear extract proteins were separated in an 8.5% polyacrylamide gel. Lanes 23-27 show HEp2 nuclear extracts which have been labeled with γ32P-ATP in the presence of 1M NaCl in vitro. The five forms of ICP22 are indicated by the numbers 1-5. The positions of ICP18 (alkaine exonuclease; Mr85,000), ICP25 (αTIF, Mr 65,000), ICP27 (Mr 63,000), and of UL34 (Mr 30,000) protein represented by the square are indicated. The letters U, T, S, R, and Q in panel C identify the phosphoprotein of nuclear extracts of infected HEp2 cells labeled with γ32p− ATP in vitro. Approximately 2 μg of nuclear extract was suspended in 50 μl of kinase buffer containing 50 mM Tris HCl, 1M NaCl, 0.1% NP40, 50mM KCl, 20mM MgCl2, 3 mM MgAc, 1 mM dithiothreitol, and 5 μCi of γ32p-ATP and incubated at 37° C. for 20 mins. The reactions were terminated by denaturation with sodium dodecyl sulfate.
- The present invention provides a process of identifying a substance for its anti-herpes simplex viral ability. Such a process comprises the steps of:
- a) preparing a model system of phosphorylating a substrate of the herpes
simplex virus U L13 gene product; - b) selecting a substance suspected of having anti-herpes simplex viral acivity; and
- c) testing for the ability of said substance to modulate phosphorylation of said substrate and thus anti-herpes simplex viral acivity in said model system.
- The expression product of herpes simplex
virus gene U L13 catalyses the transfer of a phosphate moiety from a phosphate donor to a substrate. That is, theU L13 gene product functions as a protein kinase. - Substrates for the
U L13 gene product protein kinase include a number of proteins found in herpes simplex virus infected cells and proein products of particular herpes simplex gene expression. Exemplary and preferred infected cell protein (ICP) substrates are designated ICP0 and ICP22. ICP22 is a gene product of herpes simplex virus regulatory gene α22. ICP22 is also referred to herein as α22 protein. - Exemplary and preferred gene product substrates are the gene products of herpes simplex virus US11 gene, herpes
simplex virus U L26 gene, herpes simplex virus UL26.5 gene or herpes simplex virus UL47 gene. - The herpes simplex virus UL26 gene product functions as a protease enzyme. Herpes simplex virus UL26.5 gene product is thought to be a substrate for that protease. The herpes simplex virus US11 gene product acts as an anti-terminating agent for transcription of the U L34 gene.
- At least some of the substrates of
U L13 gene product kinase activity play a role in viral replication and appear late in viral infection. Where infection occurs with a virus deficient inU L13 gene product expression, viral replication is inhibited and those substrate molecules are altered (ICP22, the UL47 gene product) or substantially decreased in abundance (the US11, U126, UL26.5 gene products). - In accordance with those observations, a model system for studying phosphorylation of
U L13 gene product substrates preferably comprises an effective catalytic amount of a herpessimplex virus U L13 gene product. - In a preferred embodiment, such a model system is prepared by forming an admixture by reacting an effective catalytic amount of herpes
simplex virus U L13 gene product with an effective amount of a substrate whose phosphorylation is catalysed by said herpessimplex virus U L13 gene product in a liquid medium containing a phosphate donor. - S Herpes
simplex virus U L13 gene product is preferably obtained from cells or organisims infected with the virus. Means for isolating and purifying products of viral gene expression in infected cells are well known in the art. A suitable substrate for use in a process of the present invention can also be obtained from infected cells. - The following examples illustrate particular embodiments of the present invention and are not limiting of the specification and claims in any way.
- The derivation of viruses used in this study were as described in Table 1.
TABLE 1 The phenotype and genotype of HSV-1 mutants used in this study. Virus Genotypea Phenotype HSV-1(F) Wild type TK+, PKUS3 +, PKUL13 + HSV-1(F) Δ305 ΔU L23/ ΔU L24TK−, PKUS3 +, PKUL13 + R7040 ΔUL23/ ΔU L24,ΔU S3TK−, PKUS3 −, PKUL13 + R7041 ΔUS3 TK+, PKUS3 −, PKUL13 + R7306 US3(R) TK+, PKUS3 +, PKUL13 + R7350 ΔUL23/ ΔU L24,ΔU S3, UL13iTK+, PKUS3 −, PKUL13− R7351 ΔUL23/ ΔU L24,ΔU S3,ΔU L13TK−, PKUS3 −, PKUL13 − R7352 ΔUL23/ ΔU L24,ΔU S3, UL13(R)TK−, PKUS3 −, PKUL13 + R7354 ΔUL23/ ΔU L24, UL13iTK+, PKUS3 +, PKUL13 − R7355 ΔUL23/ ΔU L24,ΔU L13TK−, PKUS3 +, PKUL13 − R7357 ΔUL23, ΔU S3, UL13i(R)TK−, PKUS3 −, PKUL13 + R7358 ΔUL23, UL13i(R) TK−, PKUS3 +, PKUL13 + R325 Δα22 α22− - The
U L13 gene is non-essential in cell culture. The construction and genotype of the recombinant viruses R7350, R7351, R7354, and R7355, detailed in FIG. 1 and its legend, follows the protocols described earlier (Post, et al., 1981), and involves the selection of recombinant viruses containing a chimeric α27-tk gene inserted in or near the target gene, followed by selection of the recombinant from which both the tk gene and the target sequences have been deleted. Verification of the structure of genetically engineered viruses was by Southern analysis (Southern, E. M., 1975) shown in FIG. 2. To guard against introduction of adventitious mutations, the assays included viruses designated with an (R) in which the deleted sequences were restored by marker rescue with a small fragment. All four recombinant viruses replicated on rabbit skin, 143TK−, HEp2, Vero, and BHK cells. During construction of the recombinant viruses, however, it was noted that viruses deleted in theU L13 gene (ΔUL13) yielded fewer plaques which were also of smaller size than those of the wild type virus, a property shared with mutants in theU L12 gene encoding the alkaline exonuclease (Weller, et al., 1990). These properties are not due to a deletion or a decrease in the amount of theU L12 gene product inasmuch asU L13− mutants produced amounts of alkaline exonuclease comparable to those of wild type viruses (FIG. 3). The impairment in growth and plaque formation was due to the deletion or inactivation of theU L13 gene inasmuch as the wild type phenotype was restored by marker rescue of the gene. We conclude that theU L13 gene is non essential in cell culture either in the presence or absence of theU S3 gene, but that viral replication may be significantly impaired in some cell lines in the absence of theU L13 protein. - The novel phosphoproteins present in cells infected with the ΔUS3 viruses are not dependent upon the
U L13 gene product. - The four phosphoproteins (labeled ad in FIG. 4) were shown elsewhere (Purves, et al., 1992) to be present and associated with U L34 protein in 32P-labeled lysates of BHK cells infected with recombinant viruses in which either the
U S3 gene had been deleted or which contained site specific mutations in the PK target site of the UL34 protein. In order to determine whether these proteins are phosphorylated byU L13 but only when UL34 protein is incompetent in turningU L13 off, we examined the phosphoproteins in cells infected with both single mutants (ΔUL13) or double mutants (ΔU L13, ΔUS3). As illustrated in FIG. 4, 3, 5, and 6, the tetrad (a, b, c, and d) of novel phosphoproteins was present in cells infected with alllanes ΔU S3 viruses, regardless of whether theU L13 gene was present, deleted (ΔUL13) or disrupted by insertion (UL13i). These results do not support the hypothesis thatU L13 gene product is involved in the association of the novel phosphoproteins with the unphosphorylated form of UL34 protein. - Disruption or deletion of the
U L13 open reading frame alters the post-translational modification of the α22 protein in vivo. - As shown in FIG. 4, panel A, lysates of BHK cells infected with
ΔU L13 or UL13i viruses contained a prominent 32P-labeled band migrating with an apparent Mr of 70,000 (indicated by the closed circle). The appearance of this band did not correlate with deletions in theU S3 gene. Further studies of the lysates of BHK cells (FIG. 5, panel B, lanes 1-12) or of nuclear extracts of HEp2 cells (FIG. 6, panel A, lanes 1-8) revealed five phosphoprotein species ranging in Mr. from 70,000 to 82,000 (identified in FIG. 5,lane 2, and FIG. 6,lane 2, by numbers 1-5) whose absence, presence and amount were consistently correlated to the state of theU L13 gene. Specifically, in cell lysates or nuclear extracts of cells infected withΔU L13 or UL13i recombinants, the Mr 70,000 phosphoprotein (No. 5) appeared to be either hyperphosphorylated or present in increased amounts, whereas the higher Mr phosphoproteins (No 1-3) appear to be either absent or hypophosphorylated (FIG. 5, panel B, lanes 5-8; FIG. 6, panel A, lanes 5-8). Inasmuch as restoration of theU L13 sequences restored the wild type phenotype in both BHK cells (FIG. 5, panel B, lanes 9-11) and HEp-2 cells (data not shown) the observed phenotype reflected theU L13 genotype. - To determine whether the phosphorylated proteins designated by the numbers 1-5 corresponded to known viral phosphoproteins, electrophoretically separated lysates of infected cells were electrically transferred to a nitrocellulose sheet and reacted with antibodies to ICP27 (H1117), αTIF (LP1), ICP22 (R77), and the alkaline exonuclease (Q1) (Ackermann, et al., 1984; Ackermann, et al., 1985; Banks, et al., 1985). The results (FIG. 5, panel A and FIG. 6, panel B) indicate that the phosphoproteins 1-5 comigrate with post-translationally modified forms of the ICP22. Conclusive evidence of the identity of these proteins is based on the absence of these bands in cells infected with R325 (FIG. 5 panels A and B, lane 12), a recombinant virus from which a portion of the α22 gene had been deleted (Post, et al., 1981). As a control for equal infectivity, the same immunoblot (FIG. 5 panel A) was also reacted with monoclonal antibody to the ICP27. In BHK cells infected with
U L13− virus, (FIG. 5, panel A, lanes 5-8, 15-16) most of the ICP22 was present as a Mr 70,000 protein (No 5) and only a small amount comigrated with the No. 4 band. A similar pattern was seen in nuclear extracts of HEp-2 cells infected withU L13− viruses (FIG. 6 panel B, compare lanes 9-11 with 12-15) except that traces of the higher molecular weight species (No. 2 and 3) were present. We conclude that theU L13 gene product mediates post-translational processing which is associated with phosphorylation of ICP22 to the apparent higher molecular weight species (bands No. 14). - The phosphoprotein profiles of nuclear extracts obtained from HEp2 cells infected with the
U L13 deletion viruses labeled with γ32P-ATP in vitro differed significantly from those labeled with 32Pi in vivo. - Nuclear extracts of HSV-1(F) infected cells labeled in with γ 32P-ATP in the presence of 1M NaCl exhibited five labeled bands designated as U, T, S, k and Q (FIG. 6, Panel C, lane 24). Inasmuch as phosphoproteins U, T, S and R were absent from cells infected with
ΔU S3 viruses (FIG. 6, panel C, lanes 25-26), they represent proteins whose phosphorylation is either directly or indirectly mediated by theU S3 PK. Phosphoproteins S and R are likely to be theU S3 PK itself, which forms a doublet and is known to autophosphorylate. Phosphoprotein U was identified as the alkaline exonuclease by its reactivity with the Q1 monoclonal antibody. Phosphoprotein T is presently under investigation. Phosphoprotein Q, however, which has an apparent Mr of 57,000, is present only in cells infected with viruses encoding anintact U L13 gene. - A recent report (Cunningham, et al., 1992) identified a kinase activity present in the nuclei of infected cells which phosphorylates a M r 57,000 protein. The activity maps between
U L9 andU L15 genes and is immunoprecipitable with anti-UL13 antisera. The authors suggested that the observed event may beU L13 autophosphorylation. This interpretation is consistent with our results, but whether the actual kinase activity isU L13 itself has not been established. - The
U L13 protein, like theU S3 PK, is non-essential for HSV-1 replication in cell culture, although viral yields appear to be diminished. The predicted sequence of theU L13 protein contains amino acid motifs which are characteristic of the catalytic domains of eukaryotic PKs, and possibly bacterial phosphotransferases (Smith, et al., 1989; Chee, et al., 1989). By analogy with theU S3 PK (Purves, et al., 1986; Purves, et al., 1987; Purves, et al., Eur. J. Biochem. 1987), determination of the enzymatic activity will require studies on purified protein. Whereas theU S3 PK is mainly a cytoplasmic kinase (Purves, et al., 1986), theU L13 protein is readily detected in the nucleus (Cunningham, et al., 1992). Whereas the major substrate of theU S3 PK is the UL34 membrane protein (Purves, et al., 1992), the prominent target ofU L13 is ICP22. Furthermore, whereasU S3 is conserved only among the alphaherpesviruses (McGeoch, et al., 1986; Baer, et al., 1984; Davison, et al, 1986), theU L13 gene is conserved among all three herpesvirus subfamilies (varicella zoster, (Davison, et al, 1986), human cytomegalovirus, (Chee, et al., 1989),human herpes virus 6, (Lawrence, et al., 1990) and Epstein Barr Virus, (Baer, et al., 1984). - The M r 70,000 species (No. 5) of ICP22 and trace amounts of higher mol. weight species (No. 24) predominate in extracts of cells infected with the
U L13− viruses. The stepwise increases in molecular weight between the five ICP22 subspecies are consistent with, but not indicative of, successive phosphorylations of the protein and appear to be cell type specific. The phosphorylation of the Mr. 70,000 species (No. 5) is independent of theU L13 protein. Subsequent phosphorylation of ICP22 may represent direct phosphorylations by theU L13 protein or by another infected cell PK activated by theU L13 gene product. We note that ICP22 is predicted to have 45 serine and 28 threonine amino acids. The majority of these residues are flanked by clusters of acidic amino acids, particularly at the N-terminus betweenamino acid 38 and 118, and at the C-terminus between amino acids 296 and 385. The nuclear PK activity described by Cunningham et al. (Cunningham, et al., 1992) which phosphorylates theU L13 protein also has a preference for acidic target sites of the type present in ICP22. - ICP22 has been implicated in the trans-activation of viral genes and as a protein involved in extending the host range of HSV-1 in cell culture (Sears, et al., 1985). In non permissive cells (e.g. rabbit skin, hamster, and rat cell lines) late protein synthesis was grossly reduced. ICP22 appears to exert a regulatory function which is complemented by cellular proteins in some cell lines. Since ICP22 is among the first. viral proteins made after infection, it is conceivable that the
U L13 protein modifies ICP22 late in infection thereby altering its function. In this respect, theU L13 gene may serve to regulate late gene expression via ICP22. It is noteworthy thatU L13− virus exhibited impaired growth on rabbit skin cells, and that in BHK cells infected withU L13− virus, ICP22 was less extensively processed than in infected HEp2 cells. The significance of the modifications of ICP22 are currently under study. - Further analyses of the protein profiles of cells infected with the
U L13 deletion viruses have related that the levels of specific viral late proteins are dramatically reduced in amount when compared to the levels observed in cells infected with either wild type virus or virus in which theU L13 gene has been repaired. The proteins which are reduced include the products of US11, UL26 (protease) and UL26.5 (protease substrate), and three other viral proteins, two of which may correspond to the tegument proteins encoded by theU L47 and UL49 genes. This list of affected viral proteins cannot be considered as all incluive, as many other viral protein levels have not yet been closely examined. It is noteworthy that not all late viral proteins appear reduced in cells infected with theU L13− virus. Specifically, αTIF and glycoprotein C proteins accumulate to wild type levels in the cells infected with theU L13 deletion viruses, indicating that the modified ICP22 may target only certain viral genes. - Equally important, late genes do not appear to be the only kinetic class affected by the
U L13 mediated phosphorylation of ICP22. For example, while two α gene products, ICP4 and ICP27, accumulate to wild type levels in cells infected with either the ICP22 deletion of theU L13 deletion viruses, the amounts of another α gene product ICP0 are significantly reduced to both. This observation is particularly significant, as ICP0 appears to play a critical role in several aspects of the viral life cycle. Numerous studies have implicated it as a promiscuous transactivator of viral gene expression during lytic replication. Recombinant viruses in which the α0 gene has been deleted demonstrate impaired reactivation from latency. - In order to determine whether the reduced accumulation of proteins in the cells infected with the ICP22 and the
U L13 deletion viruses were due to reduced levels of mRNA in infected cells, the levels of mRNA encoding two of the affected proteins, ICP0 andU S11, were measured by northern blot analysis. Both ICP0 andU S11 mRNA levels were clearly decreased in cells infected with the mutant viruses, indicating either decreased transcription rates of these genes, or decreased stability of these mRNAs, in the absence of theU L13 induced modification of ICP22.
Claims (4)
1. A process of identifying a substance for its anti-herpes simplex viral ability comprising the steps of:
a) preparing a model system of phosphorylating a substrate of the herpes simplex virus UL13 gene product;
b) selecting a substance suspected of having anti-herpes simplex viral acivity; and
c) testing for the ability of said substance to modulate phosphorylation of said substrate and thus anti-herpes simplex viral acivity in said model system.
2. The process according to claim 1 wherein said substrate is infected cell protein 0, infected cell protein 22, herpes simplex virus US11 gene product, herpes simplex virus UL6 gene product, herpes simplex virus UL26.5 gene product or herpes simplex virus UL47 gene product.
3. The process according to claim 1 wherein said model system comprises an effective catalytic amount of a herpes simplex virus UL13 gene product.
4. The process according to claim 1 wherein preparing said model system comprises forming an admixture by reacting an effective catalytic amount of herpes simplex virus UL13 gene product with an effective amount of a substrate whose phosphorylation is catalysed by said herpes simplex virus UL13 gene product in a liquid medium containing a phosphate donor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/870,931 US20020015944A1 (en) | 1992-08-18 | 2001-05-30 | Herpes simplex virus 1 UL 13 gene product: methods and compositions |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/931,631 US5334498A (en) | 1992-08-18 | 1992-08-18 | Herpes simplex virus 1 UL13 gene product: methods and compositions |
| US24520994A | 1994-05-17 | 1994-05-17 | |
| US09/870,931 US20020015944A1 (en) | 1992-08-18 | 2001-05-30 | Herpes simplex virus 1 UL 13 gene product: methods and compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US24520994A Continuation | 1992-08-18 | 1994-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020015944A1 true US20020015944A1 (en) | 2002-02-07 |
Family
ID=25461104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/931,631 Expired - Fee Related US5334498A (en) | 1992-08-18 | 1992-08-18 | Herpes simplex virus 1 UL13 gene product: methods and compositions |
| US09/870,931 Abandoned US20020015944A1 (en) | 1992-08-18 | 2001-05-30 | Herpes simplex virus 1 UL 13 gene product: methods and compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/931,631 Expired - Fee Related US5334498A (en) | 1992-08-18 | 1992-08-18 | Herpes simplex virus 1 UL13 gene product: methods and compositions |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5334498A (en) |
| EP (1) | EP0656113B1 (en) |
| JP (1) | JPH08500185A (en) |
| AT (1) | ATE140793T1 (en) |
| AU (1) | AU5005293A (en) |
| DE (1) | DE69303822T2 (en) |
| WO (1) | WO1994004920A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050142622A1 (en) * | 2002-01-31 | 2005-06-30 | Sanders Mitchell C. | Method for detecting microorganisms |
| US20060039894A1 (en) * | 2004-06-24 | 2006-02-23 | Ian Mohr | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US20070128589A1 (en) * | 2005-07-13 | 2007-06-07 | Sanders Mitchell C | Substrates, sensors, and methods for assessing conditions in females |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334498A (en) * | 1992-08-18 | 1994-08-02 | Arch Development Corporation | Herpes simplex virus 1 UL13 gene product: methods and compositions |
| US5814442A (en) * | 1994-06-10 | 1998-09-29 | Georgetown University | Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid |
| US5869234A (en) * | 1996-01-05 | 1999-02-09 | President And Fellows Of Harvard College | Method of identifying compounds which modulate herpesvirus infection |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
| WO2025089259A1 (en) * | 2023-10-23 | 2025-05-01 | 国立大学法人 東京大学 | Recombinant live attenuated herpes simplex virus type 1 vaccine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334498A (en) * | 1992-08-18 | 1994-08-02 | Arch Development Corporation | Herpes simplex virus 1 UL13 gene product: methods and compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0361749B1 (en) * | 1988-09-27 | 1995-02-08 | Dana Farber Cancer Institute | A vector comprising a replication competent HIV-I provirus and a heterologous gene |
| US5223391A (en) * | 1990-02-21 | 1993-06-29 | President And Fellows Of Harvard College | Inhibitors of herpes simplex virus replication |
-
1992
- 1992-08-18 US US07/931,631 patent/US5334498A/en not_active Expired - Fee Related
-
1993
- 1993-08-12 AU AU50052/93A patent/AU5005293A/en not_active Abandoned
- 1993-08-12 JP JP6506378A patent/JPH08500185A/en active Pending
- 1993-08-12 EP EP93919969A patent/EP0656113B1/en not_active Expired - Lifetime
- 1993-08-12 DE DE69303822T patent/DE69303822T2/en not_active Expired - Fee Related
- 1993-08-12 WO PCT/US1993/007547 patent/WO1994004920A1/en not_active Ceased
- 1993-08-12 AT AT93919969T patent/ATE140793T1/en not_active IP Right Cessation
-
2001
- 2001-05-30 US US09/870,931 patent/US20020015944A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334498A (en) * | 1992-08-18 | 1994-08-02 | Arch Development Corporation | Herpes simplex virus 1 UL13 gene product: methods and compositions |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050142622A1 (en) * | 2002-01-31 | 2005-06-30 | Sanders Mitchell C. | Method for detecting microorganisms |
| US9017963B2 (en) | 2002-01-31 | 2015-04-28 | Woundchek Laboratories (Us), Inc. | Method for detecting microorganisms |
| US20060039894A1 (en) * | 2004-06-24 | 2006-02-23 | Ian Mohr | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US20110236415A1 (en) * | 2004-06-24 | 2011-09-29 | New York University | Virulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US8252277B2 (en) | 2004-06-24 | 2012-08-28 | New York University | Virulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US8709397B2 (en) | 2004-06-24 | 2014-04-29 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US20070128589A1 (en) * | 2005-07-13 | 2007-06-07 | Sanders Mitchell C | Substrates, sensors, and methods for assessing conditions in females |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE140793T1 (en) | 1996-08-15 |
| EP0656113B1 (en) | 1996-07-24 |
| US5334498A (en) | 1994-08-02 |
| JPH08500185A (en) | 1996-01-09 |
| DE69303822T2 (en) | 1997-01-16 |
| WO1994004920A1 (en) | 1994-03-03 |
| DE69303822D1 (en) | 1996-08-29 |
| EP0656113A1 (en) | 1995-06-07 |
| AU5005293A (en) | 1994-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Purves et al. | The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein alpha 22. | |
| DeLuca et al. | Physical and functional domains of the herpes simplex virus transcriptional regulatory protein ICP4 | |
| Purves et al. | The herpes simplex virus 1 protein kinase encoded by the US3 gene mediates posttranslational modification of the phosphoprotein encoded by the UL34 gene | |
| Purves et al. | Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. | |
| Rice et al. | Herpes simplex virus immediate-early protein ICP22 is required for viral modification of host RNA polymerase II and establishment of the normal viral transcription program | |
| Purves et al. | Herpes simplex virus 1 protein kinase is encoded by open reading frame US3 which is not essential for virus growth in cell culture | |
| Kato et al. | Herpes simplex virus 1-encoded protein kinase UL13 phosphorylates viral Us3 protein kinase and regulates nuclear localization of viral envelopment factors UL34 and UL31 | |
| Jacobson et al. | Importance of the herpes simplex VirusUL24Gene for productive ganglionic infection in mice | |
| Smith et al. | Characterization of the regulatory functions of the equine herpesvirus 1 immediate-early gene product | |
| Heineman et al. | The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22 | |
| van Zeijl et al. | The human cytomegalovirus UL97 protein is phosphorylated and a component of virions | |
| Desai et al. | The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection | |
| Zhao et al. | Regulatory function of the equine herpesvirus 1 ICP27 gene product | |
| Xia et al. | Role of protein kinase A and the serine-rich region of herpes simplex virus type 1 ICP4 in viral replication | |
| US5334498A (en) | Herpes simplex virus 1 UL13 gene product: methods and compositions | |
| Baudoux et al. | Mutational analysis of varicella-zoster virus major immediate-early protein IE62 | |
| Holden et al. | Characterization of the regulatory function of the ICP22 protein of equine herpesvirus type 1 | |
| Ng et al. | Partial substitution of the functions of the herpes simplex virus 1 UL13 gene by the human cytomegalovirus UL97 gene | |
| Albright et al. | The herpes simplex virus UL37 protein is phosphorylated in infected cells | |
| Wolf et al. | Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase | |
| Lin et al. | Functional analysis of virion host shutoff protein of pseudorabies virus | |
| Lillycrop et al. | Inhibition of herpes simplex virus infection by ectopic expression of neuronal splice variants of the Oct-2 transcription factor | |
| Daikoku et al. | The US3 protein kinase of herpes simplex virus type 2 is associated with phosphorylation of the UL12 alkaline nuclease in vitro | |
| Ottosen et al. | Phosphorylation of the VP16 transcriptional activator protein during herpes simplex virus infection and mutational analysis of putative phosphorylation sites | |
| Zhu et al. | Overexpression of the herpes simplex virus type 1 immediate-early regulatory protein, ICP27, is responsible for the aberrant localization of ICP0 and mutant forms of ICP4 in ICP4 mutant virus-infected cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |